LLY Nov 2024 500.000 call
| Previous close | 401.25 |
| Open | 409.25 |
| Bid | 385.40 |
| Ask | 393.35 |
| Strike | 500.00 |
| Expiry date | 2024-11-15 |
| Day's range | 401.25 - 409.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 162 |
ZacksRVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
ReutersUS Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent, saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs. Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, signed a $16.5 billion deal to buy Catalent in February to boost supply of Wegovy, Novo's blockbuster GLP-1 weight loss drug.
ZacksNVS or LLY: Which Is the Better Value Stock Right Now?
NVS vs. LLY: Which Stock Is the Better Value Option?
